{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:18:22Z","timestamp":1790090302700,"version":"4.0.1"},"reference-count":38,"publisher":"FapUNIFESP (SciELO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:p>Tem se tornado pr\u00e1tica comum em nosso pa\u00eds a troca de medicamentos prescritos por outros similares, por produtos gen\u00e9ricos e at\u00e9 mesmo por produtos manipulados, muitas vezes ignorando-se preceitos b\u00e1sicos de bioequival\u00eancia, permutabilidade, estabilidade e caracter\u00edsticas espec\u00edficas do composto farmac\u00eautico. No caso de drogas de \u00edndice terap\u00eautico estreito, como a levotiroxina, esses problemas se agravam colocando em s\u00e9rio risco a efic\u00e1cia do tratamento e a sa\u00fade do paciente. Revemos a legisla\u00e7\u00e3o pertinente ressaltando as caracter\u00edsticas da levotiroxina e os efeitos adversos que limitam a permutabilidade do composto.<\/jats:p>","DOI":"10.1590\/s0004-27302011000700001","type":"journal-article","created":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T15:05:53Z","timestamp":1331910353000},"page":"429-434","source":"Crossref","is-referenced-by-count":4,"title":["Levotiroxina e o problema da permutabilidade de drogas de estreito intervalo terap\u00eautico"],"prefix":"10.1590","volume":"55","author":[{"given":"Laura Sterian","family":"Ward","sequence":"first","affiliation":[{"name":"Universidade Estadual de Campinas, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"891","DOI":"10.7326\/0003-4819-142-11-200506070-00006","article-title":"Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000","volume":"142","author":"Haas JS","year":"2005","journal-title":"Ann Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1208\/s12248-009-9142-z","article-title":"Bioequivalence: its history, practice, and future","volume":"11","author":"Midha KK","year":"2009","journal-title":"AAPS J"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1377\/hlthaff.28.2.546","article-title":"Patients' perceptions of generic medications","volume":"28","author":"Shrank WH","year":"2009","journal-title":"Health Aff","ISSN":"https:\/\/id.crossref.org\/issn\/0092-8577","issn-type":"print"},{"key":"ref4","article-title":"Resolu\u00e7\u00e3o - RDC n.\u00ba 16 de 2 de mar\u00e7o de 2007: Aprovar o Regulamento T\u00e9cnico para Medicamentos Gen\u00e9ricos","year":"2007","journal-title":"Di\u00e1rio Oficial da Uni\u00e3o"},{"key":"ref5","series-title":"Design and analysis of bioavailability and bioequivalence studies","author":"Chow SC","year":"2000"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000085690","article-title":"Biosimilars, generic versions of the first generation of therapeutic proteins: do they exist?","volume":"149","author":"Crommelin D","year":"2005","journal-title":"Contrib Nephrol","ISSN":"https:\/\/id.crossref.org\/issn\/0302-5144","issn-type":"print"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejpb.2009.02.014","article-title":"Biosimilars: science, status, and strategic perspective","volume":"72","author":"Kresse GB","year":"2009","journal-title":"Eur J Pharm Biopharm","ISSN":"https:\/\/id.crossref.org\/issn\/0939-6411","issn-type":"print"},{"key":"ref8","series-title":"Guideline on the investigation of bioequivalence","year":"2010"},{"issue":"9","key":"ref9","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.1987.03400090084039","article-title":"Generic drugs and the prescribing physician","volume":"258","author":"Nightingale SL","year":"1987","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0009-9236(98)90100-X","article-title":"What are narrow therapeutic index drugs?","volume":"63","author":"Levy G","year":"1998","journal-title":"Clin Pharmacol Ther","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9236","issn-type":"print"},{"key":"ref11","series-title":"1997 Docket number 97N-0314, Prescription Drugs Products","first-page":"43535","volume":"62"},{"issue":"1","key":"ref12","first-page":"2","article-title":"Bioequivalence and interchangeability of narrow therapeutic range drugs: Canadian Society for Pharmaceutical Sciences Discussion","volume":"1","author":"Palylyk-Colwell E","year":"1998","journal-title":"J Pharm Pharmaceut. Sci"},{"key":"ref13","series-title":"Health Protection Branch, Health Canada, Conduct and analysis of bioavailability and bioequivalence studies part A: oral dosage formulations, not in modified released form, of drugs used for systemic effects, having complicated or variable pharmacokinetics","year":"1992"},{"issue":"14","key":"ref14","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/ajhp\/54.14.1630","article-title":"FDA position on product selection for 'narrow therapeutic index' drugs","volume":"54","year":"1997","journal-title":"Am J Health Syst Pharm","ISSN":"https:\/\/id.crossref.org\/issn\/1079-2082","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"d2238","DOI":"10.1136\/bmj.d2238","article-title":"Levothyroxine dose and risk of fractures in older adults: nested case-control study","volume":"342","author":"Turner MR","year":"2011","journal-title":"BMJ","ISSN":"https:\/\/id.crossref.org\/issn\/0959-8138","issn-type":"print"},{"issue":"8","key":"ref16","first-page":"933","article-title":"Update on subclinical hyperthyroidism","volume":"83","author":"Donangelo I","year":"2011","journal-title":"Am Fam Physician","ISSN":"https:\/\/id.crossref.org\/issn\/0002-838X","issn-type":"print"},{"issue":"7","key":"ref17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM200102153440707","article-title":"Thyroid hormone and the cardiovascular system","volume":"344","author":"Klein I","year":"2001","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref18","first-page":"397012","article-title":"Screening for thyroid dysfunction in pregnancy: is it worthwhile?","author":"Lazarus JH","year":"2011","journal-title":"J Thyroid Res"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/01.AOG.0000152345.99421.22","article-title":"Subclinical hypothyroidism and pregnancy outcomes","volume":"105","author":"Casey BM","year":"2005","journal-title":"Obstet Gynecol","ISSN":"https:\/\/id.crossref.org\/issn\/0029-7844","issn-type":"print"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/105072502753451986","article-title":"Overt and subclinical hypothyroidism complicating pregnancy","volume":"12","author":"Abalovich M","year":"2002","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1046\/j.1365-2265.2003.01822.x","article-title":"Maternal hypothyroxinaemia during early pregnancy and subsequent child development: a 3-year follow-up study","volume":"59","author":"Pop VJ","year":"2003","journal-title":"Clin Endocrinol"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/thy.2009.0311","article-title":"Benefits of thyrotropin suppression vs. the risks of adverse effects in differentiated thyroid cancer","volume":"20","author":"Biondi B","year":"2010","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"11","key":"ref23","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","article-title":"Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer","volume":"19","author":"Cooper DS","year":"2009","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"key":"ref24","series-title":"Projeto Diretrizes","volume-title":"C\u00e2ncer diferenciado da tireoide: seguimento","author":"Ward LS","year":"2011"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4158\/EP0362.OR","article-title":"Adverse event reporting in patients treated with levothyroxine: results of the pharmacovigilance task force survey of the American Thyroid Association, American Association of Clinical Endocrinologists, and The Endocrine Society","volume":"16","author":"Hennessey JV","year":"2010","journal-title":"Endocr Pract"},{"key":"ref26","series-title":"2008 Electronic Orange Book"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2265.1988.tb01219.x","article-title":"Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment","volume":"28","author":"Carr D","year":"1988","journal-title":"Clin Endocrinol"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"E42","DOI":"10.1208\/aapsj070105","article-title":"Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate","volume":"7","author":"Blakesley VA","year":"2005","journal-title":"AAPS J"},{"key":"ref29","series-title":"Formul\u00e1rio Terap\u00eautico Nacional 2008: Minist\u00e9rio da Sa\u00fade S\u00e9rie B. Textos B\u00e1sicos de Sa\u00fade"},{"issue":"6","key":"ref30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/FPC.0b013e3283448d19","article-title":"Association of the UGT1A1-53(TA)n polymorphism with L-thyroxine doses required for thyrotropin suppression in patients with differentiated thyroid cancer","volume":"21","author":"Vargens DD","year":"2011","journal-title":"Pharmacogenet Genomics"},{"issue":"8","key":"ref31","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1089\/thy.2011.0029","article-title":"Levothyroxine replacement doses are affected by gender and weight, but not age","volume":"21","author":"Devdhar M","year":"2011","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"5","key":"ref32","first-page":"345","article-title":"The difficult patient: drug interaction and the influence of concomitant diseases on the treatment of hypothyroidism","volume":"54","author":"Ward LS","year":"2010","journal-title":"Arq Bras Endocrinol Metabol","ISSN":"https:\/\/id.crossref.org\/issn\/0004-2730","issn-type":"print"},{"key":"ref33","series-title":"Questions and answers on levothyroxine products","year":"2007"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1210\/jc.2009-1625","article-title":"Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy","volume":"95","author":"Flynn RW","year":"2010","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1590\/S0004-27302000000600006","article-title":"Estudo de ades\u00e3o ao tratamento do hipotiroidismo","volume":"44","author":"Bagattoli RM","year":"2000","journal-title":"Arq Bras Endo Metab"},{"issue":"4","key":"ref36","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1210\/jc.2008-1696","article-title":"High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over","volume":"94","author":"Somwaru LL","year":"2009","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref37","series-title":"Endocrine insider","year":"2011"},{"issue":"7","key":"ref38","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1089\/1050725041517138","article-title":"Joint statement on the U.S. Food and Drug Administration's decision regarding bioequivalence of levothyroxine sodium","volume":"14","year":"2004","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v55n7\/01.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T10:33:44Z","timestamp":1561458824000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302011000700001&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0004-27302011000700001"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302011000700001","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}